biochemical society(the)
biochemical society(the) Company Information
Company Number
00892796
Website
https://www.biochemistry.orgRegistered Address
first floor, 10 queen street place, london, EC4R 1BE
Industry
Activities of other membership organisations n.e.c.
Activities of professional membership organisations
Telephone
02038802795
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
-0%
biochemical society(the) Estimated Valuation
Pomanda estimates the enterprise value of BIOCHEMICAL SOCIETY(THE) at £3.1m based on a Turnover of £4.7m and 0.65x industry multiple (adjusted for size and gross margin).
biochemical society(the) Estimated Valuation
Pomanda estimates the enterprise value of BIOCHEMICAL SOCIETY(THE) at £0 based on an EBITDA of £-23k and a 4.31x industry multiple (adjusted for size and gross margin).
biochemical society(the) Estimated Valuation
Pomanda estimates the enterprise value of BIOCHEMICAL SOCIETY(THE) at £33.9m based on Net Assets of £11.1m and 3.06x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Biochemical Society(the) Overview
Biochemical Society(the) is a live company located in london, EC4R 1BE with a Companies House number of 00892796. It operates in the activities of professional membership organizations sector, SIC Code 94120. Founded in November 1966, it's largest shareholder is unknown. Biochemical Society(the) is a mature, small sized company, Pomanda has estimated its turnover at £4.7m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Biochemical Society(the) Health Check
Pomanda's financial health check has awarded Biochemical Society(The) a 3 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
6 Weak
Size
annual sales of £4.7m, make it larger than the average company (£646.1k)
£4.7m - Biochemical Society(the)
£646.1k - Industry AVG
Growth
3 year (CAGR) sales growth of -1%, show it is growing at a slower rate (5.6%)
-1% - Biochemical Society(the)
5.6% - Industry AVG
Production
with a gross margin of 61.6%, this company has a comparable cost of product (61.6%)
61.6% - Biochemical Society(the)
61.6% - Industry AVG
Profitability
an operating margin of -0.6% make it less profitable than the average company (1.8%)
-0.6% - Biochemical Society(the)
1.8% - Industry AVG
Employees
with 43 employees, this is above the industry average (10)
43 - Biochemical Society(the)
10 - Industry AVG
Pay Structure
on an average salary of £54.5k, the company has a higher pay structure (£37.6k)
£54.5k - Biochemical Society(the)
£37.6k - Industry AVG
Efficiency
resulting in sales per employee of £109.8k, this is more efficient (£87.2k)
£109.8k - Biochemical Society(the)
£87.2k - Industry AVG
Debtor Days
it gets paid by customers after 8 days, this is earlier than average (17 days)
8 days - Biochemical Society(the)
17 days - Industry AVG
Creditor Days
its suppliers are paid after 14 days, this is quicker than average (28 days)
14 days - Biochemical Society(the)
28 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Biochemical Society(the)
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 81 weeks, this is less cash available to meet short term requirements (158 weeks)
81 weeks - Biochemical Society(the)
158 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 24%, this is a higher level of debt than the average (19.1%)
24% - Biochemical Society(the)
19.1% - Industry AVG
BIOCHEMICAL SOCIETY(THE) financials
Biochemical Society(The)'s latest turnover from December 2023 is £4.7 million and the company has net assets of £11.1 million. According to their latest financial statements, Biochemical Society(The) has 43 employees and maintains cash reserves of £3.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4,723,000 | 4,731,000 | 4,370,000 | 4,870,000 | 5,808,000 | 5,519,000 | 4,817,000 | 4,669,000 | 2,484,000 | 5,043,000 | 5,466,000 | 6,034,000 | 6,134,000 | 6,402,000 | 9,235,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | -29,000 | 61,000 | -689,000 | -432,000 | 248,000 | 144,000 | -184,000 | ||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,000 | 13,000 | 13,000 | 12,000 | 11,000 | |
| Pre-Tax Profit | 251,000 | -828,000 | -414,000 | 613,000 | -61,000 | 650,000 | 129,000 | -639,000 | -219,000 | -1,577,000 | -502,000 | -297,000 | 406,000 | 204,000 | -165,000 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 251,000 | -828,000 | -414,000 | 613,000 | -61,000 | 650,000 | 129,000 | -639,000 | -219,000 | -1,577,000 | -502,000 | -297,000 | 406,000 | 204,000 | -165,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 251,000 | -828,000 | -414,000 | 613,000 | -61,000 | 650,000 | 129,000 | -639,000 | -219,000 | -1,577,000 | -502,000 | -297,000 | 406,000 | 204,000 | -165,000 |
| Employee Costs | 2,344,000 | 2,448,000 | 3,418,000 | 2,088,000 | 2,429,000 | 2,560,000 | 1,982,000 | 2,327,000 | 1,289,000 | 3,121,000 | 3,090,000 | 3,311,000 | 2,925,000 | 2,729,000 | 4,151,000 |
| Number Of Employees | 43 | 42 | 39 | 41 | 42 | 37 | 37 | 39 | 46 | 53 | 66 | 71 | 72 | 73 | 76 |
| EBITDA* | -23,000 | 72,000 | -565,000 | -283,000 | 390,000 | 314,000 | 121,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 4,000 | 8,000 | 9,000 | 9,000 | 6,036,000 | 1,506,000 | 1,913,000 | 1,957,000 | 1,872,000 | 3,036,000 | 2,501,000 | 2,568,000 | 3,400,000 | 3,453,000 | 3,882,000 |
| Intangible Assets | 0 | 0 | 2,000 | 64,000 | 154,000 | 86,000 | 0 | 32,000 | 23,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 10,518,000 | 10,099,000 | 7,079,000 | 6,221,000 | 0 | 8,555,000 | 9,068,000 | 8,807,000 | 9,578,000 | 8,868,000 | 7,806,000 | 8,376,000 | 6,621,000 | 6,810,000 | 6,237,000 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 10,522,000 | 10,107,000 | 7,090,000 | 6,294,000 | 6,190,000 | 10,147,000 | 10,981,000 | 10,796,000 | 11,473,000 | 11,904,000 | 10,307,000 | 10,944,000 | 10,021,000 | 10,263,000 | 10,119,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7,000 | 13,000 | 11,000 | 9,000 | 14,000 | 17,000 | 12,000 | 14,000 |
| Trade Debtors | 112,000 | 106,000 | 133,000 | 229,000 | 227,000 | 217,000 | 146,000 | 119,000 | 75,000 | 100,000 | 203,000 | 145,000 | 327,000 | 241,000 | 261,000 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 315,000 | 353,000 | 243,000 | 313,000 | 0 | 437,000 | 431,000 | 371,000 | 252,000 | 383,000 | 518,000 | 574,000 | 403,000 | 278,000 | 368,000 |
| Cash | 3,630,000 | 4,523,000 | 8,900,000 | 8,930,000 | 8,278,000 | 2,579,000 | 1,963,000 | 2,075,000 | 1,791,000 | 1,041,000 | 2,320,000 | 2,289,000 | 2,267,000 | 2,445,000 | 2,031,000 |
| misc current assets | 0 | 0 | 0 | 0 | 57,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 4,057,000 | 4,982,000 | 9,276,000 | 9,472,000 | 8,947,000 | 3,233,000 | 2,540,000 | 2,572,000 | 2,131,000 | 1,535,000 | 3,050,000 | 3,022,000 | 3,014,000 | 2,976,000 | 2,674,000 |
| total assets | 14,579,000 | 15,089,000 | 16,366,000 | 15,766,000 | 15,137,000 | 13,380,000 | 13,521,000 | 13,368,000 | 13,604,000 | 13,439,000 | 13,357,000 | 13,966,000 | 13,035,000 | 13,239,000 | 12,793,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 71,000 | 122,000 | 172,000 | 114,000 | 312,000 | 274,000 | 156,000 | 249,000 | 217,000 | 274,000 | 365,000 | 328,000 | 321,000 | 385,000 | 397,000 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,237,000 | 2,431,000 | 3,859,000 | 3,076,000 | 0 | 3,108,000 | 2,722,000 | 2,790,000 | 2,565,000 | 2,772,000 | 2,610,000 | 2,835,000 | 2,545,000 | 2,685,000 | 2,883,000 |
| total current liabilities | 2,308,000 | 2,553,000 | 4,031,000 | 3,190,000 | 3,396,000 | 3,382,000 | 2,878,000 | 3,039,000 | 2,782,000 | 3,046,000 | 2,975,000 | 3,163,000 | 2,866,000 | 3,070,000 | 3,280,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 1,190,000 | 1,375,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 1,190,000 | 1,375,000 | 0 | 199,000 | 1,015,000 | 124,000 | 1,515,000 | 1,480,000 | 1,587,000 | 1,334,000 | 69,000 | 686,000 | 1,771,000 | 0 | 1,617,000 |
| total liabilities | 3,498,000 | 3,928,000 | 4,031,000 | 3,389,000 | 4,411,000 | 3,506,000 | 4,393,000 | 4,519,000 | 4,369,000 | 4,380,000 | 3,044,000 | 3,849,000 | 4,637,000 | 3,070,000 | 4,897,000 |
| net assets | 11,081,000 | 11,161,000 | 12,335,000 | 12,377,000 | 10,726,000 | 9,874,000 | 9,128,000 | 8,849,000 | 9,235,000 | 9,059,000 | 10,313,000 | 10,117,000 | 8,398,000 | 10,169,000 | 7,896,000 |
| total shareholders funds | 11,081,000 | 11,161,000 | 12,335,000 | 12,377,000 | 10,726,000 | 9,874,000 | 9,128,000 | 8,849,000 | 9,235,000 | 9,059,000 | 10,313,000 | 10,117,000 | 8,398,000 | 10,169,000 | 7,896,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -29,000 | 61,000 | -689,000 | -432,000 | 248,000 | 144,000 | -184,000 | ||||||||
| Depreciation | 6,000 | 9,000 | 8,000 | 12,000 | 10,000 | 40,000 | 53,000 | 66,000 | 35,000 | 101,000 | 124,000 | 149,000 | 142,000 | 170,000 | 305,000 |
| Amortisation | 0 | 2,000 | 62,000 | 90,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | -7,000 | -6,000 | 4,000 | 2,000 | -5,000 | -3,000 | 5,000 | -2,000 | 14,000 |
| Debtors | -32,000 | 83,000 | -166,000 | 315,000 | -427,000 | 77,000 | 87,000 | 163,000 | -394,000 | -238,000 | 2,000 | -11,000 | 211,000 | -110,000 | 629,000 |
| Creditors | -51,000 | -50,000 | 58,000 | -198,000 | 38,000 | 118,000 | -93,000 | 32,000 | -148,000 | -91,000 | 37,000 | 7,000 | -64,000 | -12,000 | 397,000 |
| Accruals and Deferred Income | -194,000 | -1,428,000 | 783,000 | 3,076,000 | -3,108,000 | 386,000 | -68,000 | 225,000 | -45,000 | 162,000 | -225,000 | 290,000 | -140,000 | -198,000 | 2,883,000 |
| Deferred Taxes & Provisions | -185,000 | 1,375,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -421,000 | -114,000 | -750,000 | 28,000 | -30,000 | 216,000 | 2,758,000 | ||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 469,000 | 222,000 | 1,019,000 | 1,196,000 | 39,000 | 926,000 | 131,000 | -12,000 | 646,000 | -517,000 | |
| Change in Investments | 419,000 | 3,020,000 | 858,000 | 6,221,000 | -8,555,000 | -513,000 | 261,000 | -771,000 | 1,772,000 | 1,062,000 | -570,000 | 1,755,000 | -189,000 | 573,000 | 6,237,000 |
| cash flow from investments | -419,000 | -3,020,000 | -858,000 | -6,221,000 | 982,000 | -39,000 | 1,790,000 | -576,000 | -1,023,000 | 1,496,000 | -1,624,000 | 177,000 | 73,000 | -6,754,000 | |
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5,000 | 13,000 | 13,000 | 12,000 | 11,000 | |
| cash flow from financing | -331,000 | -346,000 | 372,000 | 1,038,000 | 96,000 | 150,000 | 253,000 | -859,000 | 323,000 | 703,000 | 2,029,000 | -2,164,000 | 2,081,000 | 8,072,000 | |
| cash and cash equivalents | |||||||||||||||
| cash | -893,000 | -4,377,000 | -30,000 | 652,000 | 5,699,000 | 616,000 | -112,000 | 284,000 | -529,000 | -1,279,000 | 31,000 | 22,000 | -178,000 | 414,000 | 2,031,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -893,000 | -4,377,000 | -30,000 | 652,000 | 5,699,000 | 616,000 | -112,000 | 284,000 | -529,000 | -1,279,000 | 31,000 | 22,000 | -178,000 | 414,000 | 2,031,000 |
biochemical society(the) Credit Report and Business Information
Biochemical Society(the) Competitor Analysis
Perform a competitor analysis for biochemical society(the) by selecting its closest rivals, whether from the OTHER SERVICE ACTIVITIES sector, other small companies, companies in EC4R area or any other competitors across 12 key performance metrics.
biochemical society(the) Ownership
BIOCHEMICAL SOCIETY(THE) group structure
Biochemical Society(The) has 1 subsidiary company.
biochemical society(the) directors
Biochemical Society(The) currently has 13 directors. The longest serving directors include Mr Peter Shepherd (Jan 2008) and Professor Michelle West (Jul 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Peter Shepherd | New Zealand | 62 years | Jan 2008 | - | Director |
| Professor Michelle West | England | 55 years | Jul 2017 | - | Director |
| Professor Frank Sargent | England | 54 years | Jan 2018 | - | Director |
| Professor Luciane Vieira De Mello Rigden | England | 60 years | Apr 2019 | - | Director |
| Dr Derry Mercer | England | 55 years | Jan 2021 | - | Director |
| Dr Augustin Amour | England | 57 years | Nov 2021 | - | Director |
| Professor Lisa Chakrabarti | England | 54 years | Jan 2022 | - | Director |
| Professor Nigel Hooper | England | 61 years | Jul 2022 | - | Director |
| Professor Dame Julia Goodfellow | England | 73 years | Jul 2022 | - | Director |
| Dr Susan Campbell | England | 49 years | Feb 2023 | - | Director |
P&L
December 2023turnover
4.7m
0%
operating profit
-29k
-148%
gross margin
61.7%
+0.02%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
11.1m
-0.01%
total assets
14.6m
-0.03%
cash
3.6m
-0.2%
net assets
Total assets minus all liabilities
biochemical society(the) company details
company number
00892796
Type
Private Ltd By Guarantee w/o Share Cap
industry
94990 - Activities of other membership organisations n.e.c.
94120 - Activities of professional membership organisations
incorporation date
November 1966
age
58
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
SAYER VINCENT LLP
address
first floor, 10 queen street place, london, EC4R 1BE
Bank
COUTTS & CO
Legal Advisor
BATE WELLS LLP
biochemical society(the) Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to biochemical society(the).
biochemical society(the) Companies House Filings - See Documents
| date | description | view/download |
|---|
